Ways to improve efficiency of endocrinotherapy of breast cancer: new targeted cells, new therapeutic opportunities


DOI: https://dx.doi.org/10.18565/pharmateca.2018.12.39-48

V.F. Semiglazov (1), V.V. Semiglazov (2), K.S. Nikolaev (1), G.A. Dashyan (1), A.V. Komyakhov (1), R.M. Paltuev (1), V.S. Appolonova (1), R.V. Donskikh (1), A.I. Tseluyko (1), T.Yu. Semiglazova (1), E.K. Zhiltsova (1), P.V. Krivorotko (1)

1 SRI of Oncology n.a. N.N. Petrov, St. Petersburg, Russia; 2 St. Petersburg State Medical University n.a. Acad. I.P. Pavlov, St. Petersburg, Russia
Overcoming the resistance to endocrine therapy is one of the most difficult aspects of breast cancer (BC) treatment. Studies on resistance to hormonal therapy have shown the fundamental role of cross-signaling pathways in interaction with the estrogen receptors determining resistance (PI3K/AKT/mTOR pathways). The mTOR inhibitor everolimus improves the survival of patients with hormone-receptor-positive breast cancer. Activation of the CDK4/CDK6/E2T pathway is a frequent sign of luminal ER+BC. The combination of CDK 4/6 inhibitor ribociclib and letrozol demonstrated a significant improvement in progression-free survival compared to letrozol+placebo. The combination of CDK 4/6 inhibitor palbociclib and fulvestrant showed a significant improvement in progression-free survival compared to fulvestrant+placebo.
Keywords: ER+breast cancer, PI3K/AKT/mTOR pathway, CDK4/CDK6, ESR1 mutation, aromatase inhibitors, fulvestrant, everolimus, palbociclib, ribociclib

About the Autors


Corresponding author: Kirill S. Nikolaev, Oncologist, Researcher at the Department of Breast Tumors, SRI of Oncology n.a. N.N. Petrov, St. Petersburg, Russia; e-mail: kirill.nikolaev87@gmail.com
Address: 68, Leningradskaya Street, Pesochny settlement, St. Petersburg, 197758 Russian Federation


Бионика Медиа